The global leader in the fight against blood cancers, The Leukemia & Lymphoma Society (LLS), announced the launch of its Pediatric Acute Leukemia (PedAL) Master Clinical Trial, an unprecedented international collaboration led by LLS designed to fundamentally change how children with acute leukemias are treated.

It’s a diagnosis you never want to hear: Acute Myeloid Leukaemia (AML). These three words represent a devastating diagnosis of childhood cancer with dire consequences for many families.

A new platform trial, a world first, could have transformative implications for people with resistant acute myeloid leukaemia (AML).

It is hoped that the findings will pave the way for new and more personalised therapies for acute myeloid leukaemia

Cancer researchers at Children’s Hospital of Philadelphia have won $200,000 from the Science Center, a nonprofit organization in Philadelphia that supports innovation and entrepreneurship. The award will fund one year of research to develop a commercially viable novel immunotherapeutic agent to treat acute myeloid leukemia (AML), an aggressive cancer that affects both children and adults.

Acute myeloid leukaemia (AML) is a fatal form of blood cancer in children. The survival of AML patients remains poor due to the return of disease after chemotherapy (relapse). Leukaemia stem cells (LSCs) are the major cause of relapse and Dr Wang and the team at the Children’s Cancer Institute are studying how to eradicate them without harming healthy cells.

Cancer researcher Dr Gabi Brumatti has spent years searching for new treatments for acute myeloid leukaemia (AML).

The Leukaemia Foundation welcomes the federal government $80 million investment to establish the Peter MacCallum Centre as a new base for Car-T Cell therapy and other immunotherapy clinical trials in Australia.

Professor Jacques Miller’s pioneering immunology research has been recognised with a prestigious Japan Prize, and some say it also deserves a Nobel Prize.

Emily was the first child to receive CAR-T therapy, what was then considered a risky treatment in an early clinical trial for the therapy. After today’s FDA approval of the therapy for sale, she is an icon of the treatment’s effectiveness and promise for thousands of children with leukemia that can now access the treatment.

Fifteen months ago, 15-year-old Emma Collins was dying of leukemia. With no other option, her parents took her from their home in rural Canada for a last-ditch experimental treatment at Children's Hospital of Philadelphia, a choice that families from Croatia and even beyond have made.

Melbourne researchers have shown they can stop leukaemia in its tracks by targeting a protein that puts the handbrake on cancer cell growth.

Dr Andrew Wood has won many battles in his war against child cancer, but says it's those he has lost now driving him towards new treatments in a cutting-edge research programme.

Doctor makes biggest leukaemia breakthrough in 30 years which could lead to a cure for rare form of the disease